Buy & Sell TransMedics Group Inc (TMDX) – TransMedics Group Inc Price Today
Aura AI Summary
Key Stats
- $2.61BMarket Cap
- TechnologySector
- -46.61%3M Drawdown
- $3.01BEnterprise Value
- -Dividend Yield
- 49% Buy | 51% SellTrading Activity
- 16 daysTypical Hold Time
TransMedics Group Inc (TMDX) is currently valued at a market capitalization of $2.61B, with an enterprise value of $3.01B. Over the past 52 weeks, TransMedics Group Inc has traded between a low of $61.99 and a high of $150.42, highlighting its annual price range. Over the past three months, TransMedics Group Inc has recorded a drawdown of -46.61%, reflecting recent price volatility. On average, investors hold TransMedics Group Inc for approximately 16 days, indicating typical investor behavior on the platform.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Most Recent News
Scilex shares jump 18.79% on Dream Bowl Meme Coin listing news
Scilex Holding Company saw its shares rise 18.79% after announcing that its Dream Bowl Meme Coin tokens could start trading on Biconomy Exchange as early as June 23. The listing is expected to boost liquidity and expand distribution to eligible token...

Aditxt shares plunge nearly 34% after major shareholder buys millions of shares.
Aditxt Inc. shares dropped 33.94% in after-hours trading following a disclosure that major shareholder HRT Financial LP purchased over 4.2 million shares at $0.016 each. Despite this large purchase, the stock continues to face heavy selling pressure,...

Resolution Therapeutics advances Regenerative Macrophage Therapy with new in vivo lipid nanoparticle delivery program.
Resolution Therapeutics has signed agreements to access lipid nanoparticle (LNP) technology to develop its in vivo Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. This new program aims to complement its ongoing autologou...
